Jodi Lucena-Pichardo, William Rooney, Jun 27, 2012
The Eleventh Circuit’s recent decision in Federal Trade Commission v. Watson Pharmaceuticals, Inc. (the “AndroGel” decision) addresses the latest challenge to reverse-payment settlements. The Eleventh Circuit rejected the Federal Trade Commission’s position that the lawfulness of a reverse-payment settlement depends on the perceived strength or weakness of the patent and concluded that a patent, unless previously invalidated, should be given its full exclusionary scope.
Links to Full Content
